Rasonque shrank tumors in over 30% of NSCLC patients in a small trial

In a small lung-cancer trial, tumors shrank in more than 30% of participants who received Rasonque. Revolutions Medicines' drug, also called daraxonrasib, is now moving from that early signal into a larger comparison with standard chemotherapy.

The timing matters. Just a week earlier, the same therapy had received U.S. approval for advanced pancreatic cancer. Nature, cited by STAT, now reports promise in the world's biggest cancer killer.

The lung-cancer trial was not a general test across all patients. Each participant had a tumor-promoting mutation in a member of the RAS family of proteins and had already tried other therapies. The result therefore points to a defined group: people whose disease carries that mutation and has already been treated.

Next comes the harder comparison. A larger study is underway, with participants randomly assigned to Rasonque or standard chemotherapy. That design places the early tumor-shrinkage result beside the treatment used as the benchmark; the larger study has not yet reported its findings.

So what changes now? For patients with non-small cell lung cancer carrying a RAS-family mutation after earlier therapies, Rasonque is being tested directly against standard care. It is not yet evidence that the therapy works better than chemotherapy: the larger trial is still underway, and the first result comes from a small study.